KOSDAQBiotech & Pharma141080

LigaChem Biosciences

₩54,400▲ 0.93%2026-11-18 close
Market Cap
₩2T
Turnover
₩12.3B
Volume
230K
Shares out.
37M
PER
—
PBR
2.7×
EPS
-₩5,980
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Clinical data to decide the next phase after a licensing lull

LigaChem Biosciences posted continued operating losses in the third quarter of 2026 as licensing income fell, and partner clinical data and its own clinical entries are the next checkpoints.

  1. 1

    Licensing revenue remains the core of sales. Of the third-quarter 2026 revenue of KRW 14.5 billion, licensing revenue was KRW 11.8 billion, based on the preliminary results announced on November 13, 2026.

  2. 2

    Losses have persisted. The company recorded operating losses in each year from 2022 to 2025, and net losses attributable to controlling shareholders in each of the last five quarters, totaling KRW 226.1 billion over the last four quarters.

  3. 3

    R&D spending is weighing on results. R&D expenses for 2025 rose 72.5% from the prior year to KRW 195.7 billion, as reported at the March 31, 2026 investor briefing.

  4. 4

    Funding has expanded. After KRW 500 billion from the National Growth Fund was paid in, cash on hand at the end of the third quarter of 2026 stood at KRW 832.1 billion, per the November 13, 2026 announcement.

  5. 5

    Clinical data are the next turning point. The CD19-targeted LCB73 (IKS03) recorded an objective response rate of 53%, and additional data are slated for a December 2026 medical meeting.

02

Business structure

LigaChem Biosciences is an ADC drug developer built around its ConjuAll antibody-drug conjugate platform and its proprietary PBD prodrug payload.

Its business model has two arms: licensing candidates to global pharmaceutical companies for upfront fees and milestone payments, and advancing key assets into clinical trials on its own. Its main partners are Janssen, Ono Pharmaceutical of Japan, Systimmune of China, and IKSUDA Therapeutics of the UK.

LCB14 and LCB73 (IKS03) have been licensed to IKSUDA, LCB71 to Systimmune, and LCB97 to Ono. Revenue is driven mainly by licensing income. Of third-quarter 2026 revenue of KRW 14.5 billion, licensing revenue accounted for KRW 11.8 billion, per the November 13, 2026 results announcement.

Its own pipeline includes LCB84, a TROP2-targeted ADC co-developed with Janssen, LCB02A, a claudin 18.2-targeted candidate that dosed its first patient on October 15, 2026, and candidates based on its next-generation DAR1 platform.

At its R&D Day in July 2026, the company set a target of bringing about 20 ADC candidates into clinical trials within five years. The company says it now finds antibodies itself through global CROs rather than relying mainly on external antibody sourcing.

In competition, big pharma investment in ADCs is expanding, while concerns about toxicity and resistance in existing ADCs have raised interest in next-generation platforms.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩41.4B-₩23.2B−56.0%
2025Q4₩16B-₩73.1B−458.4%
2026Q1₩35.9B-₩37.4B−104.3%
2026Q2₩5.5B-₩72B−1300.9%
2026Q3₩14.5B-₩50.4B−347.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩33.4B-₩50.4B-₩45.1B−150.8%−20.5%15.0%
2023₩34.1B-₩80.8B-₩73.7B−236.7%−49.7%27.9%
2024₩125.9B-₩20.9B₩7.8B−16.6%1.3%19.9%
2025₩141.6B-₩106.5B-₩91.6B−75.2%−18.0%29.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 33.4 billion in 2022 to KRW 34.1 billion in 2023 (up 2.2% year on year), KRW 125.9 billion in 2024 (up 268.7%), and KRW 141.6 billion in 2025 (up 12.4%). Revenue increased for three consecutive years from 2023 to 2025, and 2025 was the largest year in the 2022 to 2025 period.

Licensing revenue for 2025 was reported at KRW 121.2 billion at the March 31, 2026 investor briefing. Operating losses were KRW 50.4 billion in 2022, KRW 80.8 billion in 2023, KRW 20.9 billion in 2024, and KRW 106.5 billion in 2025, a loss in each of the four years from 2022 to 2025.

The operating margin was -16.6% in 2024, the smallest loss ratio in the period, and worsened to -75.2% in 2025. Revenue growth did not narrow losses mainly because of R&D. R&D expenses for 2025 rose 72.5% year on year to KRW 195.7 billion.

Net profit attributable to controlling shareholders turned to a KRW 7.8 billion profit in 2024 and returned to a KRW 91.6 billion loss in 2025. In 2024, the company posted a net profit despite an operating loss of KRW 20.9 billion, meaning non-operating items more than offset the operating loss.

Operating cash flow moved from KRW 78.5 billion in 2024 to negative KRW 124.5 billion in 2025.

Quarterly revenue was KRW 16 billion in the fourth quarter of 2025, KRW 35.9 billion in the first quarter of 2026, KRW 5.53 billion in the second quarter of 2026, and KRW 14.5 billion in the third quarter of 2026, swinging widely.

Because the timing and recognition period of upfront fees and milestones shift, quarterly revenue is adjusted from period to period. Third-quarter 2026 revenue fell 64.9% from KRW 41.4 billion a year earlier, largely reflecting a base effect from a KRW 15.5 billion upfront fee recognized in the third quarter of 2025.

Net losses attributable to controlling shareholders totaled KRW 226.1 billion over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026.

05

Industry analysis

Big pharmaceutical companies continue to expand their investment in the ADC market. The company says many approved ADCs have become blockbusters and reach peak sales faster than earlier drugs, though this is management's view rather than independently verified data.

As a precedent, a Mirae Asset Securities report cites GSK's 2023 licensing of a Phase 1 B7-H4 ADC based on a TOP1 payload from Hansoh Pharmaceutical for USD 1.7 billion. Technology is moving toward bispecific ADCs, dual-payload ADCs, and protein degrader-antibody conjugates to overcome limits of existing ADCs.

The company has said that a higher drug-antibody ratio in dual-payload designs can raise toxicity, so it is pursuing bispecific formats to address resistance. On payloads, the company argues that demand for new payload classes is strong.

Its position rests on more than 10 licensing deals and total deal value reported above KRW 9 trillion, a figure cited by Newspim in May 2026.

As partners advance their own trials, sublicensing by partners such as IKSUDA and Systimmune is also being discussed as an additional revenue source, which shapes the company's position in the sector.

06

Outlook

The company set a target of filing at least four investigational new drug (IND) applications in 2026, according to its March 31, 2026 investor briefing. For its own pipeline, it reconfirmed on the third-quarter 2026 earnings call a goal of starting the Phase 2 trial of LCB84, co-developed with Janssen, within 2026.

The company expects several licensing and sublicensing deals to become visible across 2026 and 2027, with IKSUDA's LCB14 and LCB73 and Systimmune's LCB71 named as sublicensing candidates. LCB14 is a candidate that shows potential to overcome resistance to Enhertu, and its Phase 1b data are awaited.

Reports suggest LCB73 could be commercialized as early as 2027 in some regions including China. Systimmune has paused LCB71 trials to finalize the optimal dose and schedule, although a first-line combination study with R-CHOP in 31 patients reported complete remission in all of them.

Additional clinical data on HER2 and CD19 ADCs are scheduled for presentation at the San Antonio Breast Cancer Symposium and the American Society of Hematology (ASH) meeting in December 2026. The CD33-targeted LCB122A is slated to present preclinical results at ASH, with an IND filing targeted for 2027. SOT106 has received FDA Fast Track and orphan drug designations, and IKS04 has received FDA IND clearance.

07

Valuation

PER
—
PBR
2.7×
ROE
-32.5%
EPS
-₩5,980
BPS
₩22,868
Dividend per share
₩0

Because net losses attributable to controlling shareholders have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. With earnings unable to explain the share price, valuation rests more on net assets and pipeline value.

The price-to-book ratio sits above 1x, meaning the shares trade at a premium to book value. Total equity at the end of 2025 was KRW 541.1 billion, of which KRW 507.6 billion belongs to controlling shareholders, and total liabilities were KRW 160.7 billion. The debt ratio rose from 15.0% in 2022 to 29.7% in 2025.

Cash on hand of KRW 832.1 billion at the end of the third quarter of 2026 includes the National Growth Fund payment and raises the scale of net assets sharply. The company does not pay dividends, so the dividend yield is close to zero.

Share price levels have tended to move with partner clinical results and licensing announcements. Over several years, the shift from a profit in 2024 to a loss again in 2025 is the starting point for any valuation discussion.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Partner clinical data accumulating

LCB73 recorded an objective response rate of 53%, with tumor shrinkage in 9 of 17 patients. LCB71 reported complete remission in all 31 patients in a first-line combination study with R-CHOP. As partner trials progress, evidence for the platform's competitiveness accumulates.

Sublicensing revenue structure

If IKSUDA and Systimmune sublicense their candidates to large pharmaceutical companies, LigaChem would share in upfront fees and milestones. The company expected several such deals across 2026 and 2027 on its third-quarter 2026 call. Partner-driven income could serve as a cash channel even when its own licensing is quiet.

Expanded funding and clinical pace

Cash on hand reached KRW 832.1 billion at the end of the third quarter of 2026 after the KRW 500 billion National Growth Fund payment. The company plans to take core assets through Phase 2 and Phase 3 on its own. Having funds in hand gives it more room to keep trials running.

09

Bear factors

Volatility in licensing revenue

Licensing revenue in the third quarter of 2026 was KRW 11.8 billion, down about 68% from KRW 36.4 billion a year earlier. The base effect from a KRW 15.5 billion upfront fee in the prior-year quarter is large.

Quarterly revenue swung from KRW 5.53 billion in the second quarter of 2026 to KRW 14.5 billion in the third quarter.

R&D burden and cumulative losses

R&D spending for 2025 rose 72.5% year on year to KRW 195.7 billion. The company has posted operating losses from 2022 through 2025, and net losses in each of the last five quarters.

Uncertainty in clinical timelines

Systimmune has paused LCB71 trials to set the optimal dose and schedule. The Phase 2 start for LCB84 is a target for 2026 rather than a confirmed date. If trial timelines slip, licensing deals and milestone receipts could also be delayed.

10

Risk factors

Clinical risk

ADC candidates can fail in clinical trials due to toxicity or resistance. The company has acknowledged that dual-payload designs may raise toxicity, so next-generation designs also need validation. Poor Phase 2 or later results would make recovering development costs difficult under the in-house strategy.

Timing and terms of licensing

The company is aware of market concern over the unclear timing of new licensing deals. IKSUDA and Systimmune, as biotech companies, may pursue third-party licensing rather than run Phase 2 and Phase 3 trials themselves. If partners' re-licensing is delayed, sublicensing income could arrive later than expected.

Cash burn and cost structure

The company says it can draw on about KRW 1 trillion in funding, but spending will rise as clinical programs expand. R&D spending in the third quarter of 2026 was KRW 54.6 billion, close to the prior-year level. Meeting the target of four to five INDs a year will require managing spending alongside cost discipline.

11

What to watch next

  1. November 16–19, 2026

    LigaChem plans to present its parallel in-house development and partnering strategy at the Jefferies Global Healthcare Conference in London. Remarks at this event may indicate progress in licensing talks.

  2. December 2026

    Additional clinical data on HER2 and CD19 ADCs, along with preclinical results for the CD33-targeted LCB122A, are slated for the San Antonio Breast Cancer Symposium and ASH. Durability of responses and safety profiles are the points to watch.

  3. By end of 2026

    Whether the LCB84 Phase 2 trial starts and whether the minimum target of four IND filings is met can be checked. Both are timelines the company has set as goals.

  4. Late 2026 through 2027

    The key question is whether several direct licensing deals and sublicensing transactions by IKSUDA and Systimmune are confirmed. The revenue share LigaChem receives will depend on the terms of those agreements.

  5. March 2027

    The 2026 annual business report will confirm full-year revenue, operating loss, cash flow, and R&D expenses. It will also include fourth-quarter 2026 results.

12

Overall view

LigaChem Biosciences generates revenue mainly from licensing income and aims to build pipeline value through its own clinical trials. Revenue rose for three consecutive years from 2023 to 2025, while operating losses continued in each year from 2022 to 2025.

In the third quarter of 2026, licensing revenue fell sharply from a year earlier, and net losses have persisted for five consecutive quarters. Cash on hand reached KRW 832.1 billion after the National Growth Fund payment, and the company is directing this capital toward expanding clinical work.

Partner trials have produced early response data for LCB73 and LCB71, but LCB71 trials have been paused while the dose is finalized. The next checkpoints are the December 2026 medical meeting data, the planned Phase 2 start for LCB84 within 2026, and the 2026 annual business report due by March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. fnnews.com
  2. m.sedaily.com
  3. securities.miraeasset.com
  4. hankyung.com
  5. m.news.nate.com
  6. newspim.com
  7. m.news.nate.com
  8. news.nate.com
  9. m.news.nate.com
  10. medifonews.com
  11. sentv.co.kr
  12. m.news.nate.com
  13. thebionews.net
  14. m.news.nate.com
  15. dailian.co.kr
  16. dailian.co.kr
  17. dailian.co.kr
  18. m.inews24.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis